MedTrace Logo

3BNC117 and 10-1074 in HIV Uninfected Adults

NCT02824536 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-04-17

No results posted yet for this study

Summary

This is a phase 1 clinical trial to evaluate the safety and pharmacokinetics of the highly neutralizing anti-human immunodeficiency virus-1 monoclonal antibodies 3BNC117 and 10-1074, when given in combination, in human immunodeficiency virus (HIV)-uninfected individuals. This study is intended to support the development of the combination of 3BNC117 and 10-1074 mAbs for use as prophylaxis against HIV infection in healthy HIV-uninfected individuals at risk for HIV infection.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

3BNC117

Intravenous Infusion of 3BNC117

DRUG

10-1074

Intravenous Infusion of 10-1074

DRUG

Placebo

Intravenous Infusion of Sterile Saline (NaCl 0.9%)

Sponsors & Collaborators

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Yehuda Cohen, MD · Rockefeller University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-23
Primary Completion
2018-01-09
Completion
2018-01-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02824536 on ClinicalTrials.gov